SM
NTLA icon

SG3 Management’s Intellia Therapeutics NTLA Stock Holding History

SG3 Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,000
Closed -$3.35M – 1209
2021
Q3 		$3.35M Sell
25,000
-54,000
-68% -$8.18M 0.1% 199
2021
Q2 		$12.8M Buy
+79,000
New +$6.15M 0.45% 45

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

SG3 Management's NTLA Position: Q4 2021 in Review

SG3 Management sold out of Intellia Therapeutics (NTLA) in Q4 2021, closing a stake of 13,000 shares — an estimated $1.74M sold.

SG3 Management first reported a position in NTLA in Q1 2021 and held it in 3 quarters. The position peaked at $4.05M in Q2 2021. 371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

  • SG3 Management reported no remaining Intellia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 13,000 Intellia Therapeutics shares in Q4 2021, an estimated $1.74M.
  • SG3 Management first reported a position in Intellia Therapeutics in Q1 2021 and held it in 3 quarters.
  • SG3 Management's Intellia Therapeutics position peaked at $4.05M in Q2 2021.
  • 371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.